- Conditions
- Metastatic Melanoma
- Interventions
- Ipilimumab, Tumor Infiltrating Lymphocytes (TIL), Administration of Lymphodepletion, Cyclophosphamide as Part of Lymphodepletion, Fludarabine as Part of Lymphodepletion, High Dose IL-2, Adoptive Cell Therapy with TIL
- Drug · Procedure · Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 817–840
of 2,274
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma (Skin)
- Interventions
- BCG vaccine, autologous tumor cell vaccine, recombinant interferon alfa, chemotherapy, cyclophosphamide
- Biological · Drug
- Lead sponsor
- AVAX Technologies
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 425 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 17
- States / cities
- Rancho Mirage, California • New Haven, Connecticut • North Miami Beach, Florida + 13 more
- Conditions
- HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor, Advanced Solid Tumors, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Pancreatic Cancer, Melanoma
- Interventions
- FATE-NK100, Cetuximab, Trastuzumab
- Drug
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- San Diego, California • Minneapolis, Minnesota • Columbus, Ohio + 1 more
- Conditions
- Advanced Malignancies, Metastatic Cancer
- Interventions
- INCAGN01876, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
- Interventions
- BNT111, Cemiplimab
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • San Francisco, California • Miami, Florida + 3 more
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Uveal Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IV Melanoma
- Interventions
- vorinostat
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Rockledge, Pennsylvania
- Conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer), Non-Small Cell Lung Cancer, MSI-H/dMMR Rectal Cancer, Squamous Cell Carcinoma Mouth, Invasive Mammary Carcinoma, Classic Hodgkin Lymphoma
- Interventions
- Dual-Energy X-ray Absorptiometry (DXA), High Resolution peripheral Quantitative Computed Tomography (HRpQCT)
- Device
- Lead sponsor
- Jessica Mezzanotte Sharpe
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma, Hepatocellular Carcinoma, Glioma, Sarcomatoid Carcinoma
- Interventions
- ADI-PEG 20
- Drug
- Lead sponsor
- Polaris Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Metastatic Melanoma, Nausea
- Interventions
- Not listed
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Wound of Skin, Non-melanoma Skin Cancer, Skin Graft Complications, Wound of Lower Leg, Wound of Knee
- Interventions
- Nanofat-seeded biological scaffold on surgical defect
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced BRAF Mutant Melanoma
- Interventions
- Trametinib 2 mg daily, hydroxychloroquine (HCQ), dabrafenib 150 mg orally twice a day
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • St Louis, Missouri • New Brunswick, New Jersey + 1 more
- Conditions
- Mucosal Melanoma of the Head and Neck
- Interventions
- Pembrolizumab, Hypofractionated radiation therapy
- Drug · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Melanoma (Skin)
- Interventions
- therapeutic autologous lymphocytes, fludarabine phosphate
- Biological · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma
- Interventions
- AZD6750, rilvegostomig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more
- Conditions
- Melanoma, Neoplasm
- Interventions
- Karenitecin (BNP1350)
- Drug
- Lead sponsor
- BioNumerik Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Melanoma, Renal Cell Carcinoma, Metastatic
- Interventions
- IL-2 and Nivolumab
- Drug
- Lead sponsor
- Gregory Daniels
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Choroidal Melanoma, Indeterminate Lesions
- Interventions
- Standard of Care, AU-011
- Other · Drug
- Lead sponsor
- Aura Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Royal Oak, Michigan • Portland, Oregon • Greenville, South Carolina + 4 more
- Conditions
- Anxiety
- Interventions
- Normal Education Material, Vignette
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Metastatic Melanoma
- Interventions
- Bevacizumab, Everolimus
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 15
- States / cities
- Fort Myers, Florida • Lakeland, Florida • Orlando, Florida + 12 more
- Conditions
- Melanoma
- Interventions
- Physical Examination, Solar Simulated Light
- Procedure · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, HER2/Neu Negative, Melanoma, Non-Small Cell Lung Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Rectal Carcinoma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Triple-Negative Breast Carcinoma, TP53 Gene Mutation, Unresectable Solid Neoplasm
- Interventions
- Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
- Other · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Breast Cancer, Ovarian Cancer, Cervical Cancer, Testicular Cancer, Colon Rectal Cancer, Melanoma (Skin Cancer), Endometrial Cancer, Sarcoma, Thyroid Cancer
- Interventions
- Adapted patient navigation program targeting adolescent and young adult cancer survivors
- Behavioral
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin)
- Interventions
- Bempegaldesleukin, Nivolumab
- Biological
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 765 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 62
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more
- Conditions
- Melanoma
- Interventions
- IO102/IO103, Nivolumab-Relatlimab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 9
- States / cities
- Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more